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a b s t r a c t
Background: The Glial Cell-line derived neurotrophic factor (GDNF) is part of the TGF-b superfamily and is
abundantly expressed in the central nervous system. Changes in GDNF homeostasis have been reported
in affective disorders.
Aim: To assess serum GDNF concentration in elderly subjects with late-life depression, before antide-
pressant treatment, as compared to healthy elderly controls.
Methods: Thirty-four elderly subjects with major depression and 37 age and gender-matched healthy
elderly controls were included in this study. Diagnosis of major depression was ascertained by the SCID
interview for DSM-IV and the severity of depressive symptoms was assessed by the Hamilton Depression
Rating Scale (HDRS-21). Serum GDNF concentration were determined by sandwich ELISA.
Results: Patients with major depression showed a signiﬁcant reduction in GDNF levels as compared to
healthy elderly controls (p < 0.001). Also, GDNF level was negatively correlated with HDRS-21 scores
(r ¼ 0.343, p ¼ 0.003).
Discussion: Our data provide evidence that GDNF may be a state marker of depressive episode in older
adults. Changes in the homeostatic control of GDNF production may be a target to development of new
antidepressant strategies.
 2011 Elsevier Ltd. All rights reserved.
1. Introduction
Several lines of evidence suggest a widespread abnormality in
neurotrophic cascades in age-related neuropsychiatric disorders,
such as Alzheimer’s disease and late-life depression (Teixeira et al.,
2010). Most data derive from studies assessing circulating levels of
BDNF and NGF, showing a signiﬁcant reduction of circulating neu-
rotrophins in these patients which correlates with the stage of
cognitive impairment and the severity of depressive symptoms
(Forlenza et al., 2010a, b; Yu et al., 2008; Diniz et al., 2010a). Also,
these cascades can be a target for therapeutical interventions as
many drugs currently used to treat these disorders increase the
concentration of these factors (de Sousa et al., 2011; Brunoni et al.,
2008; Leyhe et al., 2008). In addition, other conditions, such as
cerebrovascular changes and the senescence process itself, may have
a signiﬁcant impact on neurotrophic cascades homeostasis (Tapia-
Arancibia et al., 2008; Lee et al., 2006; Alleva and Francia, 2009).
The Glial Cell-line derived neurotrophic factor (GDNF) is part of
the Transforming Growth Factor b (TGF-b) superfamily and is
abundantly expressed in the CNS (Airaksinen and Saarma, 2002). It
exerts its effects by the activation of GDNF-receptor a1 (GRFa1) and
the “Rearranged during Transfection” Protooncogene (RET) receptor
(Airaksinen and Saarma, 2002). In the adult CNS, it plays amajor role
in the protection of catecholaminergic, dopaminergic and cholin-
ergic neurons (Pascual et al., 2008), as well as, axonal regeneration
after injury (Straten et al., 2002).
Changes in GDNF homeostasis have been reported in patients
with affective disorders. Reduced mRNA expression in leukocytes
as well as reduced GDNF levels in serum have been reported in
patients with major depression and bipolar disorder (Otsuki et al.,
2008; Zhang et al., 2008, 2010). However, increased GDNF circu-
lating levels have also been reported in patients during manic and
depressive episodes in bipolar patients (Barbosa et al., 2011; Rosa
et al., 2006), and in patients with unipolar depression in brain
tissue (Michel et al., 2008). In addition, one study reported signif-
icantly lower peripheral GDNF levels in euthymic adult patients
with previous history of unipolar depressive disorder and bipolar
disorder (Takebayashi et al., 2006).
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However, few studies addressed the role of GDNF in late-life
depressive disorder. A recent study assessed peripheral GDNF
levels in elderly subjects with major depression (Wang et al., 2011).
In this work, GDNF serum levels were signiﬁcantly increased in
elderly subjects with late-onset depression (LOD) as compared to
gender and age-matched healthy subjects. Given the paucity of data
on peripheral GDNF levels in late-life depression and the contra-
dictory ﬁndings in the literature, our aim is to compare serum
GDNF levels in elderly subjects with late-life depression vs. age and
gender-matched controls. Speciﬁc clinical characteristics of the
late-life depression may inﬂuence the pattern of neurobiological
changes observed in these patients. These include, for instance, the
association between cerebrovascular disease and later age of onset
of the ﬁrst depressive episode (Alexopoulos et al., 1997), the
increase of pro-inﬂammatory status in elderly patients with non-
late onset recurrent depression (Diniz et al., 2010b,c), or the
higher GSK3B enzymatic activity in patients with more severe
depressive episode and cognitive impairment (Diniz et al., 2011).
Therefore, we further addressed whether changes on serum GDNF
levels is associated to the severity of depressive symptoms and
cognitive impairment, the age of onset of late-life depression and
history of previous depressive episode.
2. Methods
2.1. Patients’ recruitment and assessment
Elderly subjects with evidence of current major depressive
episodewere recruited to this study (n¼34), being16with late-onset
major depressive (LOD, ﬁrst depressive episode after 65 years-old)
and 18 with non-late onset depression (non-LOD, ﬁrst depressive
episode before 65 years-old). All patients are part of a cohort dedi-
cated to the study of the neurobiology of late-life depression (Diniz
et al., 2010b, 2010c). The diagnosis of major depressive disorder
(ﬁrst or recurrent episode) was made according to DSM-IV criteria
(American Psychiatric Association, 2000) following the Structured
Clinical Interview for DSM-IV disorders (SCID) (First et al., 2002).
Patients were free of any antidepressant treatment for at least one
month prior the initial clinical and laboratorial assessments.
The severity of the depressive symptoms was evaluated by the
scores on the 21-item Hamilton Depression Rating Scale (HDRS-21)
(Hamilton, 1960). Cognitive assessment was carried out with the
Cambridge Cognitive test (CAMCOG) (Roth et al., 1986; Nunes et al.,
2008) and the Mini-mental state examination (MMSE) (Folstein
et al., 1975).
Thirty-seven healthy elderly subjects, with no evidence of
current psychiatric or cognitive disorders, were included in this
study as a comparison group. They had no evidence of current axis
1 DSM-IV psychiatric diagnosis and HDRS-21 scores below 7.
Among the subjects in the comparison group, 18 had history of
a previous depressive episode and were on full remission, for at
least 6 months (HDRS-21 < 7), at the time of clinical and labo-
ratorial assessment.
All patients and subjects in the comparison group comprise of
subsample of elderly subjects enrolled in a prospective clinical
study on cognitive aging (Diniz et al., 2008; Forlenza et al., 2010a,
b). They underwent the same clinical, cognitive and psychiatric
work-up as the depressed patients. The elderly subjects in the
comparison group were age and gender-matched to the elderly
depressed patients.
2.2. Sample collection and GDNF analysis
Five milliliters of blood were drawn from each subject by
venipuncture at 8e10 a.m. before clinical assessment. Samples
were immediately centrifuged 2 at 3000g for 10 min, and serum
was kept frozen at 70 C until assayed.
Serum GDNF concentration was measured according to the
procedure provided by the manufacturer using sandwich ELISA kits
for GDNF (DuoSet, R&D Systems, Minneapolis, MN, USA). All
samples were assayed in duplicate. The detection limits for these
assays were 10 pg/mL. Concentration is expressed as pg/mL.
2.3. Statistical analysis
GDNF serum levels did not show a normal distribution in this
sample (KolmogoroveSmirnoff test, p¼ 0.005).We log-transformed
the GDNF levels to normalize its distribution and to be able to carry
out parametric statistical analyses. Student t test was carried out to
assess mean differences of GDNF serum level and other continuous
variables between depressed patients and controls. Chi-square with
Fisher exact test analyses were carried out to assess differences in
the frequency of dichotomous variables between depressed patients
and controls. Pearson analyses were carried out to assess the
correlation betweenGDNF levels and socio-demographic, severity of
depressive symptoms and cognitive performance.
All statistical analyses were carried with the Software Package
for Social Science v. 14.0 for Windows (SPPS, Chicago, IL).
3. Results
Table 1 shows the socio-demographic and clinical characteris-
tics of the study sample. Patients with late-life depression showed
signiﬁcantly lower scores on the MMSE and CAMCOG and had
fewer years of formal education. We carried out analysis of
covariance (ANCOVA) to control for the confounding effect of
education on the cognitive performance. The scores on MMSE and
CAMCOG remained signiﬁcantly lower in the depressed patients as
compared to elderly controls (MMSE, p ¼ 0.001; CAMCOG,
p < 0.001). The most common clinical comorbid conditions in
depressed patients were high blood pressure (85%), dyslipidemia
(62%). Their frequencies were not signiﬁcantly different from those
in control group (high blood pressure, 78%, p ¼ 0.6; dyslipidemia,
66%, p ¼ 0.8).
GDNF serum level was signiﬁcantly reduced in patients with late-
life depression as compared to healthy elderly subjects (Table 2). The
reduction in GDNF level remained statistically signiﬁcant after
controlling for the educational, cognitive performance and the
severity of depressive symptoms (analysis of covariance, F ¼ 11.35,
d.f. ¼ 1, p ¼ 0.001).
GDNF level showed a weak negative correlation with HDRS-21
scores (r ¼ 0.343, p ¼ 0.003) in the whole sample. No
Table 1
Socio-demographic and clinical characteristics of the study sample.
Diagnosis p
Gender (W/M) Comparison group (n ¼ 37) 29/8 0.6
Late-life depression (n ¼ 34) 25/9
Age (years) Comparison group (n ¼ 37) 67.8  5.4 0.1
Late-life depression (n ¼ 34) 69.7  4.5
Education (years) Comparison group (n ¼ 37) 13.5  5.1 0.002
Late-life depression (n ¼ 34) 9.8  4.5
HDRS-21 Comparison group (n ¼ 37) 1.1  1.8 <0.001
Late-life depression (n ¼ 34) 19.1  6.8
CAMCOG Comparison group (n ¼ 37) 98.4  4.5 <0.001
Late-life depression (n ¼ 34) 86.5  8.7
MMSE Comparison group (n ¼ 37) 28.9  1.4 <0.001
Late-life depression (n ¼ 34) 26.8  2.4
W: woman; M: Men. HDRS-21: Hamilton Depression Rating Scale e 21 items;
CAMCOG: Cambridge Cognitive test; MMSE: Mini-Mental State Examination.
Data values depicted as mean  standard deviation.
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signiﬁcant correlation was found between GDNF level and CAM-
COG or MMSE scores (r ¼ 0.21, p ¼ 0.08 and r ¼ 0.15, p ¼ 0.2,
respectively) or age (r ¼ 0.06, p ¼ 0.6) (Fig. 1).
Age of onset of depressive disorder did not signiﬁcantly inﬂu-
ence GDNF levels (LOD, GDNF level 2.51  0.93 vs. non-LOD, GNDF
level 2.76  0.65, p ¼ 0.36). Similarly, previous history of major
depressive episode in the comparison group did not inﬂuence
GDNF levels (positive history, GDNF level 3.32  0.61 vs. negative
history, GDNF level 3.22  0.51, p ¼ 0.8).
As serum GDNF can be signiﬁcantly reduced in patients with
cognitive impairment and dementia (Straten et al., 2009), we
stratiﬁed the patients with late-life depression according to the
presence of signiﬁcant cognitive impairment (CAMCOG scores<86)
(Nunes et al., 2008; Diniz et al., 2011). We found no signiﬁcant
differences in GDNF levels in patients with cognitive impairment
(CAMCOG<86, n ¼ 17, GDNF level ¼ 2.68  0.2; CAMOCG87,
n ¼ 17, GDNF level ¼ 2.57  0.2; p ¼ 0.7).
4. Discussion
In the present study, we found a signiﬁcant reduction in GDNF
serum levels in patients with late-life depression that was nega-
tively correlated with the severity of depressive symptoms. Our
ﬁndings were independent of patients’ age, educational level. Age
of onset of depressive disorder and previous history of depressive
episode did not inﬂuence GDNF levels in this sample.We also found
no signiﬁcant impact on GDNF levels after stratifying depressed
patients according to the presence of cognitive impairment. Taken
together, the present results suggest that decreased concentration
of serumGDNFmay be a state marker of current depressive episode
in late-life. In addition, the reduction of peripheral GDNF observed
in our study provide additional evidence that GDNF homeostasis
may play an important role in the physiopathology of major
depression in the elderly.
Normal aging process does not seem to be associated with
signiﬁcant changes on GDNF expression or on its downstream
signaling system (Alladi et al., 2010; Dass et al., 2006). However,
animal models of accelerated aging found a signiﬁcant reduction in
brain GDNF expression leading to reduced neuronal viability. We
found no signiﬁcant correlation between age and GDNF levels. This
ﬁnding was also observed in previous studies (Wang et al., 2011).
However, the reduction of GDNF in depressed patients may be
secondary to processes that lead to accelerated brain aging, such as
heightened pro-inﬂammatory status, that are also observed in
patients with late-life depression (Diniz et al., 2010d; Franchesi
et al., 2000; Cunningham et al., 2009).
Recent evidence showed that stress-related conditions increase
DNAmethylation and histone modiﬁcations in the promoter region
of GDNF gene in animal models of depression (Uchida et al., 2011).
These epigenetic changes of GDNF gene determined signiﬁcant
decrement in GDNF mRNA expression, which was rapidly reversed
by antidepressant treatment. Pre-clinical and clinical studies have
demonstrated that effective antidepressant treatment is associated
with signiﬁcant increase in GDNF levels, despite negative ﬁndings
have also been reported (Zhang et al., 2009; Hisaoka et al., 2001,
2011; Chen et al., 2001; Hisaoka et al., 2011; Golan et al., 2011).
Thus, changes in GDNF levels may be a surrogate marker of anti-
depressant response and a target for the development of new
antidepressant strategies.
GDNF has a very complex regulation and exerts multiple func-
tions in the peripheral and central nervous system. Contradictory
ﬁndings have been reported in the literature, with some studies
reporting decreased GDNF levels (Straten et al., 2009; Otsuki et al.,
2008), but others report increased GDNF levels in affective disor-
ders (Barbosa et al., 2011; Rosa et al., 2006;Michel et al., 2008;Wang
et al., 2011). Given that GDNF has an important role in the survival
and maintenance of monoaminergic neurons, it is tempting to
hypothesize that the reduction of GDNF levels may have a close
relationship to the abnormal regulation of the serotoninergic
system, as the signiﬁcant reduction of post and pre-synaptic sero-
tonin receptors observed in patients with late-life depression
(Sheline et al., 2004; Meltzer et al., 2004). Such changes were
correlated to the severity of depressive symptoms (Meltzer et al.,
2004). In this context, the negative weak correlation between
GDNF levels and depressive symptomatology may further suggest
a relationship between abnormalities in the GDNF levels and
a dysregulation of the serotoninergic system in late-life depression.
However, no study has directly evaluated the relationship of GDNF
and serotonin system changes and, thus, it is necessary additional
studies to address these hypotheses.
Our results are in contradiction with another recent study that
evaluated peripheral GDNF levels in unmedicated patients with
late-life major depression (Wang et al., 2011). This study found
a signiﬁcant increase in serum GDNF levels that correlated with
cognitive performance. Despite the similar study design, the latter
study was carried out in a population with a different ethnical
ground (i.e. chinese population) what may help to explain in part
the different results between the two studies. Additional studies
with larger samples and including subjects from other ethnical
backgrounds are necessary to conﬁrm these ﬁndings.
In conclusion, we found a signiﬁcant reduction in GDNF serum
level that was negatively correlated with depressive symptoms of
patients with late-life depression. Our data provide further support
to the evidence of widespread change in neurotrophic cascades in
affective disorders, including late-life depression. Given the
Table 2
GDNF serum levels in patients with late-life depression.
Diagnosis GDNF serum level (pg/ml) p
Late-life depression (n ¼ 34) 2.64  0.79 <0.001
Comparison group (n ¼ 37) 3.27  0.56
GDNF serum level: log-transformed data.
Data values depicted as mean  standard deviation.
Fig. 1. Scatter plot of the correlation between depressive symptoms and serum GDNF
levels.
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controversial ﬁndings regarding changes in the circulating levels of
GDNF in patients with affective disorders, additional studies are of
utmost importance to clarify the role of this neurotrophic factor in
these disorders.
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